These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 9759581)

  • 41. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
    Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
    J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interferon-alpha therapy for melanoma.
    Russell-Jones R
    Clin Exp Dermatol; 2000 Jan; 25(1):1-6. PubMed ID: 10671960
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An update on adjuvant interferon for melanoma.
    Gray RJ; Pockaj BA; Kirkwood JM
    Cancer Control; 2002; 9(1):16-21. PubMed ID: 11907462
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Update on adjuvant interferon therapy for high-risk melanoma.
    Agarwala SS; Kirkwood JM
    Oncology (Williston Park); 2002 Sep; 16(9):1177-87; discussion 1190-2, 1197. PubMed ID: 12380946
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.
    Bottomley A; Coens C; Suciu S; Santinami M; Kruit W; Testori A; Marsden J; Punt C; Salès F; Gore M; Mackie R; Kusic Z; Dummer R; Patel P; Schadendorf D; Spatz A; Keilholz U; Eggermont A
    J Clin Oncol; 2009 Jun; 27(18):2916-23. PubMed ID: 19433686
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Critical appraisal of IFN-alpha-based adjuvant therapy in stage II-III malignant melanoma.
    Eggermont AM
    Expert Rev Anticancer Ther; 2002 Oct; 2(5):563-9. PubMed ID: 12382524
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma.
    Hillner BE
    Eur J Cancer; 1998 Jul; 34 Suppl 3():S18-21. PubMed ID: 9849404
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Melanoma. A multidisciplinary approach for the general surgeon.
    Reeves ME; Coit DG
    Surg Clin North Am; 2000 Apr; 80(2):581-601. PubMed ID: 10836008
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Does adjuvant systemic therapy with interferon-alpha for stage II-III melanoma prolong survival?
    Eggermont AM; Punt CJ
    Am J Clin Dermatol; 2003; 4(8):531-6. PubMed ID: 12862495
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma.
    Navid F; Furman WL; Fleming M; Rao BN; Kovach S; Billups CA; Cain AM; Amonette R; Jenkins JJ; Pappo AS
    Cancer; 2005 Feb; 103(4):780-7. PubMed ID: 15660397
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role interferon-alpha in malignant melanoma remains to be defined.
    Eggermont AM
    Eur J Cancer; 2001 Nov; 37(17):2147-53. PubMed ID: 11677100
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant interferon-alpha for melanoma revisited: news from old and new studies.
    Punt CJ; Eggermont AM
    Ann Oncol; 2001 Dec; 12(12):1663-6. PubMed ID: 11843241
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.
    Kirkwood JM; Tarhini AA
    Forum (Genova); 2003; 13(2):127-40; quiz 187-8. PubMed ID: 14732880
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is there a role for adjuvant high-dose interferon-alpha-2b in the management of melanoma?
    Sabel MS; Sondak VK
    Drugs; 2003; 63(11):1053-8. PubMed ID: 12749732
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjuvant use of interferon alpha 2b is not justified in patients with stage IIb/III melanoma.
    Bajetta E
    Nat Clin Pract Oncol; 2008 Jan; 5(1):4-5. PubMed ID: 18043604
    [No Abstract]   [Full Text] [Related]  

  • 57. [Current aspects of adjuvant therapy of malignant melanoma].
    Kähler KC; Egberts F; Hauschild A
    Hautarzt; 2010 Jun; 61(6):523-31; quiz 532-3. PubMed ID: 20512304
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [A pilot study of low dose alpha-2b interferon in metastatic malignant melanoma with predominant subcutaneous metastases].
    Popov I; Jelić S; Kovcin V
    Srp Arh Celok Lek; 1995; 123(1-2):5-7. PubMed ID: 17974467
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment.
    Bramlette TB; Lawson DH; Washington CV; Veledar E; Johns BR; Brisman SF; Abramova L; Chen SC
    Dermatol Surg; 2007 Jan; 33(1):11-6. PubMed ID: 17214673
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.
    Jonasch E; Kumar UN; Linette GP; Hodi FS; Soiffer RJ; Ryan BF; Sober AJ; Mihm MC; Tsao H; Langley RG; Cosimi BA; Gadd MA; Tanabe KK; Souba W; Haynes HA; Barnhill R; Osteen R; Haluska FG
    Cancer J; 2000; 6(3):139-45. PubMed ID: 10882328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.